Although details of the new trade deal between the U.S. and Mexico have not yet been released, a fight is already brewing among some drug makers and consumer advocates over one provision.

At issue is a sentence in a fact sheet that was released this week by the U.S. Trade Representative. A section concerning intellectual property noted there will be 10 years of data protection for biologic drugs and an “expanded scope” of products that will be eligible for protection, although the meaning of this last phrase was not fleshed out.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Another “Deal” where the American Public loses, and corporate profits are ensured. We really need to make this kind of thing Against the Law.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy